1. Bone fractures in patients using tapentadol or oxycodone: an exploratory US claims database study.
- Author
-
Morlion BJ, Margarit C, Wild I, Karra R, Liedgens H, Sohns M, and Finco G
- Subjects
- Administrative Claims, Healthcare statistics & numerical data, Adult, Aged, Back Pain epidemiology, Databases, Factual statistics & numerical data, Female, Fractures, Bone epidemiology, Humans, Male, Medicare statistics & numerical data, Middle Aged, Osteoarthritis epidemiology, Pain, Postoperative epidemiology, Pilot Projects, Retrospective Studies, United States epidemiology, Analgesics, Opioid adverse effects, Back Pain drug therapy, Fractures, Bone chemically induced, Osteoarthritis drug therapy, Oxycodone adverse effects, Pain, Postoperative drug therapy, Tapentadol adverse effects
- Abstract
Aim: To explore fracture outcomes with tapentadol or oxycodone, two opioids with differing mechanisms of action. Materials & methods: Retrospective cohort pilot study, using MarketScan
® Commercial and Medicare Supplemental claims databases, on patients with postoperative pain, back pain, or osteoarthritis and ≥1 claim for tapentadol (n = 16,457), oxycodone (n = 1,356,920), or both (n = 15,893) between June 2009 and December 2015. Results: During 266,826 and 9,007,889 days of tapentadol and oxycodone treatment, patients evidenced 1080 and 72,275 fractures, respectively. Fracture rates per treatment-year were 1.512 for tapentadol and 3.013 for oxycodone. Conclusion: Examination of administrative claims has inherent limitations, but this exploratory analysis indicates a lower fracture rate with tapentadol than oxycodone in the analyzed dataset, which needs confirmation by further clinical trials.- Published
- 2021
- Full Text
- View/download PDF